Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,665 across all filing types
Latest filing 2013-07-10 Fund Information / Fact…
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Shareholder Newsletter - June 2013 4 pages 152.6KB
Fund Information / Factsheet Classification · 85% confidence The document is titled 'Shareholder Update June 2013' and is a newsletter providing updates on company activities, recent developments, clinical trials, and investor relations events. It includes information about product development, regulatory submissions, grants, and upcoming plans but does not contain detailed financial statements or comprehensive financial performance data. The document is a communication aimed at shareholders and investors to inform them about progress and milestones rather than a formal financial report or regulatory filing. It is longer than a brief factsheet but does not meet the criteria for an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is not a presentation, call transcript, or governance document. Given the nature and content, the best fitting category is Fund Information / Factsheet (FS), which covers brief summaries of key company facts and market information, including updates on business progress and strategy.
2013-07-10 English
Adult Surgeon approved to use Allied's CardioCel 2 pages 197.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 8 July 2013 from Allied Healthcare Group. It announces that an adult surgeon has been approved to use CardioCel under the Authorised Prescriber Scheme. The content focuses on product approval, surgeon access, and company business updates related to the product's market potential and clinical background. There are no financial statements, earnings data, regulatory certifications, or voting results. The document is a corporate announcement about product and business development rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a general company announcement about a business milestone and product approval. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory or corporate announcements that do not fit other categories. The document length is 5725 characters, which is sufficient for a substantive announcement but not a full report.
2013-07-07 English
Appendix 3B 14 pages 705.1KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form, which is a standard announcement for the issue of new shares by a company listed on the Australian Stock Exchange (ASX). It details the allotment of shares to executives as a bonus for achieving key performance indicators, including the number of shares, issue price, and compliance with ASX listing rules. The document includes detailed information about the securities issued, quotation agreements, and calculation of placement capacity under ASX rules. There are no financial statements, management discussion, or earnings data present. The document is a regulatory announcement specifically about a share issue and capital change, not a full financial report or earnings release. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length (15,000 characters) and content confirm it is the announcement itself, not just a brief notice or a report publication announcement.
2013-07-07 English
Section 708A Notice 1 page 136.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement titled 'Notice under Section 708A(5)(e) of the Corporations Act'. It notifies the market about the issue of shares to executives without disclosure under Part 6D.2 of the Corporations Act 2001, relying on section 708A(5). The content is a regulatory compliance notice about share issuance and disclosure obligations, not a full financial report or detailed capital update. It is a formal notification to the exchange about a capital transaction under specific legal provisions. Given the nature of the announcement, it fits best under 'Capital/Financing Update' (CAP) as it relates to share issuance and capital structure changes, rather than a full report or other categories.
2013-07-07 English
Replacement - Appendix 3B 14 pages 704.6KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form, which is a standard announcement for the issue of new shares by a company, in this case Allied Healthcare Group Ltd. It details the allotment of shares to executives as a bonus for achieving key performance indicators, including the number of shares, issue price, and compliance with ASX listing rules. The document includes detailed information about the securities issued, quotation agreements, and calculation of placement capacity under ASX rules. There are no financial statements, management discussion, or earnings data present. The document is a regulatory announcement specifically about a share issue and capital change, not a full financial report or earnings release. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication notice but a full regulatory announcement of a capital change.
2013-07-07 English
Allied increases stake in Ian Frazer's Coridon vaccines 2 pages 196.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 1 July 2013 from Allied Healthcare Group about increasing its stake in a vaccine technology company. It discusses business developments, investment stakes, and progress in vaccine trials. There are no financial statements, regulatory certifications, or detailed financial data. The content is an update on a capital investment and strategic stake increase in another company, which fits the category of Capital/Financing Update. The document length is about 5161 characters, which is consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2013-06-30 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.